As of the time this review was written, two KRAS G12C inhibitors have been approved by the Food and Drug Administration (FDA) as a subsequent treatment for KRAS G12C-mutated NSCLC (11). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.